Figure - available from: Vaccines
This content is subject to copyright.
SARS-CoV-2-specific neutralizing antibody levels in U/mL by the timing of booster vaccination. (A) Booster vaccination before month 6; * one sample missing for month 1. (B) Booster vaccination after month 6; * one sample missing for month 6 and month 1 after booster; and ** two patients did not receive a booster vaccination. All the patients with available data were included in the analysis, and the individual values are represented by dots. For 11 booster patients, the month 6 visit and the month 1 after booster visit were identical (cohort 1: n = 7; cohort 2: n = 1; cohort 3: n = 3). The bars show the median values, and the black dotted lines indicate the assay-specific cut-off for seropositivity. DMF: dimethyl fumarate; GA: glatiramer acetate, IFN: interferon-beta; IU: international units; n: number of patients with assessments; and TF: teriflunomide.
Source publication
The authors would like to make the following corrections to this published paper [...]
Similar publications
Introduction
A few studies have examined whether the safety and efficacy of moderate hypofractionated post-prostatectomy radiotherapy (moderate HYPORT, also called MYSTERY) are equal to those of conventionally fractionated post-prostatectomy radiotherapy (COPORT) in patients with localized prostate cancer. Therefore, this study aims to compare the...
A esclerose múltipla (EM) é uma doença degenerativa com desmielinização do sistema nervoso central. É uma das principais causas de incapacidade em jovens adultos, afetando a qualidade de vida. O presente estudo objetiva analisar os principais fatores incapacitantes e as terapêuticas mais eficazes. Foi realizada uma pesquisa no PubMed e BVS com os d...
